Document Detail


Hematocrit level as a marker of outcome in ST-segment elevation myocardial infarction.
MedLine Citation:
PMID:  20152235     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Anemia is a well-known predictor of a poor outcome in patients with ST-segment elevation myocardial infarction (STEMI). In contrast, data relating erythrocytosis to clinical outcomes in patients with STEMI are limited. Because erythrocytosis predisposes to a prothrombotic state, we hypothesized it would be associated with an increased risk of thrombotic complications in patients with STEMI undergoing primary percutaneous coronary intervention. We studied 1,042 consecutive patients with STEMI who underwent primary percutaneous coronary intervention and were a part of our primary percutaneous coronary intervention registry from 2001 to 2007. Patients with cardiogenic shock and late arrival were excluded. Patients were allocated into 3 groups according to their baseline hematocrit: anemia (<36% for women and <39% for men), normal, erythrocytosis (>46% for women and >47% for men). The clinical outcomes were assessed at 1, 6, and 12 months. The patients with anemia had the greatest clinical risk profile. Patients with erythrocytosis had a lower risk profile than the other 2 groups, except for greater rates of smoking. The mortality rates were greatest among the patients with anemia, followed by the patients with erythrocytosis, who in turn had greater short-term mortality than patients with normal hematocrit. Multivariate analysis, which included patients with erythrocytosis and those with normal hematocrit (excluding the patients with anemia), revealed that erythrocytosis was associated with an odds ratio of 4.3 (95% confidence interval 1.4 to 13, p = 0.01) for 1-month mortality. In conclusion, although not as strong a predictor of mortality as anemia, erythrocytosis might be associated with increased short-term mortality compared to a normal hematocrit. The measurement of hematocrit can be used as a useful prognostic marker in patients with STEMI.
Authors:
Gabriel Greenberg; Abid Assali; Hanna Vaknin-Assa; David Brosh; Igal Teplitsky; Shmuel Fuchs; Alexander Battler; Ran Kornowski; Eli I Lev
Related Documents :
19776685 - Cardiovascular abnormalities in patients with turner syndrome according to karyotype: o...
15136305 - The prevalence of reduced glomerular filtration rate in older hypertensive patients and...
19911855 - Valsartan: more than a decade of experience.
2831595 - Severe cardiovascular changes associated with pancuronium after cardiopulmonary resusci...
9659485 - Survey of abdominal ultrasound and diagnostic peritoneal lavage for suspected intra-abd...
1467115 - General anaesthesia and the hypereosinophilic syndrome: severe postoperative complicati...
Publication Detail:
Type:  Journal Article     Date:  2010-01-05
Journal Detail:
Title:  The American journal of cardiology     Volume:  105     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-15     Completed Date:  2010-03-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  435-40     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2010 Elsevier Inc. All rights reserved.
Affiliation:
Department of Cardiology, Rabin Medical Center, Petah-Tikva, affiliated with the Tel-Aviv University Sackler Faculty of Medicine, Tel-Aviv, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anemia / diagnosis*,  etiology,  mortality
Angioplasty, Transluminal, Percutaneous Coronary
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Anticoagulants / therapeutic use
Biological Markers / blood
Confidence Intervals
Drug Therapy, Combination
Electrocardiography
Female
Follow-Up Studies
Heart Conduction System / physiopathology*
Hematocrit*
Humans
Israel / epidemiology
Male
Middle Aged
Multivariate Analysis
Myocardial Infarction / complications,  diagnosis*,  mortality,  physiopathology,  therapy
Odds Ratio
Platelet Aggregation Inhibitors / therapeutic use
Polycythemia / diagnosis*,  etiology,  mortality
Predictive Value of Tests
Prognosis
Prospective Studies
Risk Factors
Severity of Illness Index
Smoking / adverse effects
Survival Rate
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Anticoagulants; 0/Biological Markers; 0/Platelet Aggregation Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral c...
Next Document:  Relation between thrombolysis in myocardial infarction risk score and one-year outcomes for patients...